IN THE NEWS

Company’s $300M deal could be only the beginning

read more…

JHU research led to a breakthrough for allergy vaccines. Now they’re taking aim at cancer

read more…

Immunomic Therapeutics licenses Hopkins-developed vaccine technology for $300 million

read more…

Astellas, Immunomics enter $300M allergy vaccine deal

read more…

Immunomic Therapeutics licenses Hopkins-developed vaccine technology for $300 million

read more…

DNA-based vax venture lands allergy deal with Astellas; $300M up front

read more…

Company Overview of Immunomic Therapeutics, Inc.

read more…

Shares of Astellas Pharma Inc (TYO:4503) Trade Higher In Tokyo on Immunomic Therapeutics Partnership

read more…

Immunomix lands $300 million licensing deal

read more…

Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-vax platform to prevent and treat allergies

read more…

Immunomic licenses allergy vaccine tech to Astellas for $300M

read more…

Astellas, Immunomic Therapeutics Enter Into License Deal For LAMP-vax Products

read more…

Startups: Astellas on M&A prowl to boost drug pipeline

read more…

Astellas Licenses Exclusive Rights to Immunomic’s LAMP-vax DNA Vaccine Platform

read more…

Astellas Pharma inks licensing deal for LAMP-vax products for allergic diseases

read more…

Japan’s Astellas looking for more deals to refuel drug pipeline

read more…

Astellas Pharma and Immunomic Therapeutics expand collaboration

read more…

Astellas Pharma and Immunomic Therapeutics Announce Worldwide Partnership for LAMP-vax Products for Allergic Disease

read more…

Astellas signs deal with Immunomic Therapeutics for worlwide license of LAMP-vax

read more…